TOMUS-Trial Of Mid-Urethral Slings (TOMUS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00325039 |
Recruitment Status :
Completed
First Posted : May 11, 2006
Results First Posted : September 27, 2012
Last Update Posted : January 14, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Urinary Incontinence | Procedure: retropubic mid-urethral sling (TVT) Procedure: transobturator mid-urethral sling (TVT-O and the Monarc) | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 597 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | TOMUS-Trial Of Mid-Urethral Slings |
Study Start Date : | April 2006 |
Actual Primary Completion Date : | June 2010 |
Actual Study Completion Date : | June 2013 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
retropubic mid-urethral sling (TVT) The specific TVT used was the Tension-free Vaginal Tape (Gynecare)
|
Procedure: retropubic mid-urethral sling (TVT)
This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space. |
Active Comparator: 2
transobturator mid-urethral sling (TVT-O and the Monarc) Two transobturator slings were used: the Tension-free Vaginal Tape Obturator (Gynecare), which is placed starting inside the vagina and coming out through the obturator foramen ("in-to-out") or the Monarc (American Medical System), which is placed starting in the groin area, passing through the obturator foramen, and then into the vagina ("out-to-in").
|
Procedure: transobturator mid-urethral sling (TVT-O and the Monarc)
This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space. |
- Objective Treatment Success at 12 Months [ Time Frame: 12 months ]
Objective treatment success: negative stress test, negative pad test, and no retreatment for stress urinary incontinence (SUI) including behavioral, pharmacologic or surgical procedures
A provocative stress test standardized to volume and position is performed for direct observation of urine leakage. Observed urine loss from the urethra coincidental with the Valsalva maneuver or cough is a positive test; a negative test indicates no urine loss. Pad testing quantifies the amount of urine involuntarily lost and is used to reflect everyday incontinence; it is negative if loss is <15g/24 hrs.
- Subjective Treatment Success at 12 Months [ Time Frame: 12 months ]Absence of self-reported symptoms of stress-type urinary incontinence, as assessed with the use of the Medical, Epidemiological and Social Aspects of Aging (MESA) questionnaire (responded never to all 9 MESA questions), no leakage recorded in a 3-day voiding diary and no retreatment for stress incontinence including behavioral, pharmacologic or surgical treatment.
- Patient Satisfaction at 12 Months [ Time Frame: Follow-Up ]Patient satisfaction was assessed at the 12 month visit with the questions, "how satisfied or dissatisfied are you with the result of bladder surgery related to urine leakage?" Possible responses were completely satisfied, mostly satisfied, neutral, mostly dissatisfied, and completely dissatisfied. Completely and mostly satisfied were reported as "satisfied" and neutral, most dissatisfied and completely dissatisfied as "not satisfied".
- Change in Quality of Life From Baseline to 12 Months [ Time Frame: Baseline - 12 months ]Scores on the Incontinence Impact Questionnaire range from 0 to 400 with higher scores indicating greater impact. The scores are changes from baseline to the 12 month visit (baseline - 12 months).
- Bother as Measured by the Urogenital Distress Inventory (UDI) at 12 Months [ Time Frame: 12 months ]Urogenital Distress Inventory (UDI) scores range from 0 to 300 with higher scores indicating greater distress. Scores are changes from baseline to the 12 month visit (baseline - 12 months)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Female
- Stress urinary incontinence (SUI) as evidenced by all of the following:
- Self-reported stress-type urinary incontinence symptoms, of duration ≥ 3 months
- Medical, Epidemiological and Social Aspects of Aging (MESA) stress symptom score (percent of total possible stress score) greater than MESA urge symptom score (percent of total possible urge score)
- Observation of leakage by provocative stress test at a bladder volume ≤ 300ml
- Bladder capacity ≥ 200ml by stress test
- Post-void residual (PVR) ≤ 100cc with pelvic organ prolapse (POP) Stage I or lower. If POP is Stage II-IV, PVR >100cc but ≤ 500cc is allowed
- Eligible for both retropubic and transobturator procedures
- No medical contraindications, e.g., current urinary tract infection (UTI), history of pelvic irradiation, history of lower urinary tract cancer
- American Society of Anesthesiologists (ASA) class I, II, or III
- No current intermittent catheterization
- Available for 24-months of follow-up and able to complete study assessments, per clinician judgment
- Signed consent form
Exclusion Criteria:
- Age <21 years
- Non-ambulatory (ambulatory with assistive devices does not exclude the patient)
- Pregnancy by self-report or positive pregnancy test, or self-reported intention to ever become pregnant
- Current chemotherapy or current or history of pelvic radiation therapy
- Systemic disease known to affect bladder function (i.e., Parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury or trauma)
- Urethral diverticulum, current or previous (i.e. repaired)
- Prior augmentation cystoplasty or artificial sphincter
- Implanted nerve stimulators for urinary symptoms
- History of synthetic sling for stress urinary incontinence
- <12 months post-partum
- Laparoscopic or open pelvic surgery <3 months*
- Current evaluation or treatment for chronic pelvic pain (painful bladder syndrome)
- Participation in another treatment intervention trial that might influence the results of this trial
- Need for concomitant surgery requiring an abdominal incision, use of graft material in the anterior compartment, or any use of synthetic graft material
- Enrollment in other urinary incontinence trials including SISTEr/E-SISTEr or BE-DRI/E-BE-DRI

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00325039
United States, Alabama | |
University of Alabama | |
Birmingham, Alabama, United States, 35294 | |
United States, California | |
University of California | |
San Diego, California, United States, 92103 | |
Kaiser Permanente | |
San Diego, California, United States, 92110 | |
United States, Illinois | |
Loyola University Medical Center | |
Maywood, Illinois, United States, 60153 | |
United States, Maryland | |
University of Maryland | |
Baltimore, Maryland, United States, 21201 | |
United States, Michigan | |
Oakwood Hospital/Cancer Center | |
Dearborn, Michigan, United States, 48123 | |
William Beaumont Hospital | |
Royal Oak, Michigan, United States, 48123 | |
United States, Pennsylvania | |
University of Pittsburgh | |
Pittsburgh, Pennsylvania, United States, 15213 | |
United States, Texas | |
University of Texas Southwestern | |
Dallas, Texas, United States, 75390 | |
University of Texas Health Sciences Center | |
San Antonio, Texas, United States, 78229-3900 | |
United States, Utah | |
University of Utah | |
Salt Lake City, Utah, United States, 84132 |
Study Chair: | Ann Gormley, M.D. | Dartmouth-Hitchcock Medical Center |
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | HealthCore-NERI |
ClinicalTrials.gov Identifier: | NCT00325039 |
Other Study ID Numbers: |
DK58229 |
First Posted: | May 11, 2006 Key Record Dates |
Results First Posted: | September 27, 2012 |
Last Update Posted: | January 14, 2014 |
Last Verified: | December 2013 |
Urinary Incontinence, Stress Surgery |
Urinary Incontinence Enuresis Urination Disorders Urologic Diseases Lower Urinary Tract Symptoms |
Urological Manifestations Behavioral Symptoms Elimination Disorders Mental Disorders |